Sorbact® is a registered trademark owned by ABIGO Medical ABlogo
Sorbact® Technology

Bacteria can’t resist Sorbact®
– it’s the law of nature

Based on natural processes and physical interactions, Sorbact® safely removes bacteria to prevent and treat infection without releasing active agents into the wound.

Sorbact technology logo and Sorbact surface background

Sorbact® Technology

Sorbact® Technology, a Swedish innovation with proven success in treating wounds, can be accredited to pioneering Nobel prize-winning work. This paved the way for further research on bacterial surface properties, which was used to develop Sorbact® Technology.

icon for binding

Bind

  • The DACC™-coated surface of Sorbact® has special characteristics and hydrophobic properties
  • Bacteria naturally bind and anchor to the unique Sorbact® surface
  • Also binds endotoxins that may impair wound healing*

*In vitro data

Inhibit

  • The bacteria are irreversibly bound, growth is inhibited and they are simply pacified
  • Endotoxins are shown not to be released from the bacteria*
  • No mechanism of antimicrobial resistance is expected with Sorbact®

*In vitro data

icon for removal

Remove

  • Bound bacteria, fungi and endotoxins are safely removed
  • The bacterial load in the wound bed is reduced
  • Reduced bioburden supports natural wound healing

Presenting the Sorbact® Technology

play

Sorbact® advantages

No contraindications and low risk of allergies

Reduces the bioburden in wounds1, 2

Immediate onset of action3

Development of bacterial or fungal resistance is not expected

No release of active agents into the wound4

Suitable for prolonged treatment

Does not promote the bacterial release of endotoxins5

No known antimicrobial resistance

Sorbact® is not only highly effective against common wound bacteria including MRSA6 and VRE but also targets fungi. With the Sorbact® mode of action, unlike certain antimicrobial substances that kill microbes, development of bacterial or fungal resistance is not expected, and it can be used for a prolonged period of time.

References

1.Gentili V, Gianesini S, et al. 2012. Panbacterial real-time PCR to evaluate bacterial burden in chronic wounds treated with Cutimed Sorbact. Eur J Clin Microbiol Infect Dis. 31(7):1523-1529.link
2.Mosti G, Magliaro A, et al. 2015. Comparative study of two antimicrobial dressings in infected leg ulcers: a pilot study. J Wound Care. 24(3):121-122, 124-127.link
3.Data on file, a. ABIGO Medical
4.Data on file, b. ABIGO Medical
5.Budi Susilo Y and Husmark J. 2019. DACC coated wound dressing and endotoxin: Investigation on binding ability and effect on endotoxin release from gram-negative bacteria. EWMA 2019. 2019;EP167.
6.Ronner AC, Curtin J, et al. 2014. Adhesion of meticillin-resistant Staphylococcus aureus to DACC-coated dressings. J Wound Care. 23(10):484, 486-488.link

Unsupported browser

This site probably won't work great in Internet Explorer. We generally only support the recent versions of major browsers like Chrome, Firefox, Safari and Edge.